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an estimated calculation of costs-to-charges from the Medicare
Cost Report. Regression modeling with log transformation was
employed to compare differences in ﬁxed hospital costs (those
insensitive to volume), variable costs (those sensitive to volume),
and post-operative LOS. Control variables included age, gender,
All Patient Reﬁned-Diagnosis Related Group severity codes,
region, hospital teaching status, bed size, population served
(urban or rural), and primary payer. RESULTS: A total of 82,788
discharges were included. The models demonstrated that patients
who received Gelfoam + thrombin had higher ﬁxed and variable
costs (+6.1% and +7.3%, respectively, p < 0.01) and Surgicel +
thrombin patients had higher ﬁxed and variable costs (+18% and
+10%, p < 0.01, respectively) compared to FloSeal only. In terms
of ﬁxed costs, the predicted increase was $15,956 for Gelfoam +
thrombin and $18,639 for Surgicel + thrombin patients. In
terms of variable costs, the predicted increase was $25,413
per Gelfoam + thrombin and $24,909 per Surgicel + thrombin
patient. Surgicel+ thrombin patients also had higher (+6%,
p < 0.01) post-operative LOS compared to FloSeal patients.
CONCLUSION: FloSeal demonstrated signiﬁcant cost reductions
and post-operative LOS, compared to other commonly-used
products. Limited prospective reimbursements based on a DRG
system make it necessary for health care providers to consider
more cost-effective surgical aids for spinal surgeries.
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OBJECTIVE: We assessed the cost-effectiveness of dental
implant 1st line strategy versus ﬁxed partial denture (and
denture) in patients suffering from one single missing tooth.
METHODS: The model used a simulation decision framework
over a 20-year period. Potential treatment switches can occur
every 5 years. Transition probabilities came from literature,
epidemiological reports or expert opinions. They have been
programmed using speciﬁc distribution ranges to simulate the
patients and practice variability, and to take into account param-
eters uncertainty. Direct medical costs have been assessed accord-
ing to a speciﬁc cost survey in France. Probabilistic sensitivity
analyses were conducted using 5000 Monte-Carlo simulations
generating conﬁdence intervals of model outcomes. RESULTS:
The cost distribution indicates a peak at €3000 for the bridge
strategy. The distribution for the implant strategy is more ﬂat,
showing the maximum ranging from €2500 to €3500. The model
simulations establish that total mean cost of the bridge 1st line
strategy is €4385 per patient over 20 years (minimum: €1850;
maximum: €17,267), providing 69% of success rate. Total mean
cost of the implant 1st line strategy is €3517 per patient over 20
years (minimum: €1990 Euros; maximum: €10,221 Euros), with
92% of success rate. Differences are statistically signiﬁcant for
both total mean costs (p < 0.001) and success rate (p < 0.001).
The mean cost-effectiveness (cost per functional dental unit in
position) is shown in Figure 3c. It indicates that the bridge
strategy is signiﬁcantly higher (p < 0.001) than the implant strat-
egy with €6286/success versus 3819 Euros/success respectively.
CONCLUSION: This simulation modeling approach is the very
ﬁrst robust model in the ﬁeld of implantology. Implant as the 1st
line strategy appears to be the “dominant” strategy, considering
the lower overall costs and the higher success rate.
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OBJECTIVE: For 20 years, thromboprophylactic strategies (TSs)
have been used after total hip replacement (THR). Our objective
was to conduct a comprehensive cost effectiveness analysis (CEA)
of TSs for THR from the health payer perspective. METHODS:
We extracted national data for Veteran patients receiving THR,
including 1-year follow-up of all heath care utilization and
complications of venous thromboembolic events (VTE: deep vein
thrombosis, pulmonary embolism), thombocytopenia, bleeding,
and death. Diagnostic codes were used to identify most compli-
cations. A comparative CE model, incorporating fondaparinux,
was developed. Incremental cost-effectiveness ratios (ICERs)
were calculated to compare TSs. Life-years gained (LYG) were
calculated using actuarial tables for life expectancy. Since fonda-
parinux was rarely used in the VA, we applied rates from pub-
lished trials and used our data to estimate proportional increases
in complication rates for fondaparinux from day 50 through one
year. We applied VA costs. Fondaparinux costs were based upon
mean costs of outcomes of the other TSs. One-way sensitivity
analyses (SA) were performed by incorporating the mean prob-
abilities of DVT in the other TSs into the least-costly TS or
decreasing the costs of complication arms by one standard devia-
tion in all but the least-costly TS. RESULTS: There were 1722
patients, 90 VTEs, and 48 deaths. Dalteparin was dominant;
the least-costly per patient with fewest VTEs ($18,850, 2.4%)
compared to warfarin ($18,953, 6.4%), enoxaparin ($19,965,
2.7%), enoxaparin/warfarin ($24,809, 21.6%), and fonda-
parinux ($20,759, 5.2%). Thus, ICERS indicated more costs and
more events with other TSs. Deaths occurred in 2.4% of dalte-
parin patients versus 2.3% for enoxaparin and, estimated, 1.0%,
for fondaparinux, thus ICERS for LYG were $35,754/LYG and
$6381/LYG, respectively. Dalteparin and other treatments were
dominant over warfarin (2.9% deaths) and enoxaparin/warfarin
(6.0% deaths)for LYG. Each SA showed dalteparin remained the
least-costly TS per VTE avoided. CONCLUSION: Dalteparin
was slightly more effective and less costly.
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OBJECTIVE: There is a lack of cost effectiveness (CE) analyses
of thromboprophylactic strategies (TSs) for total knee replace-
ment (TKR) that incorporate outpatient care, long-term follow-
up, or complications besides venothrombotic events (VTE: deep
vein thrombosis, pulmonary embolism). The objective was to
assess the CE of TSs for TKR from the health payer perspective
including complications of VTE, hemorrhage, thrombocyto-
penia, and death. METHODS: We searched national Veterans
Affairs (VA) datasets for all health care use, outcomes and VA
costs for patients receiving TKR within one year. Our follow-up
was one year. Diagnostic codes were used to identify complica-
tions. Life-years gained (LYG) were calculated using actuarial
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